KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Financing Activities (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Cash from Financing Activities for 13 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 80.82% year-over-year to $26.7 million, compared with a TTM value of -$33.5 million through Dec 2025, down 124.0%, and an annual FY2025 reading of -$33.5 million, down 124.0% over the prior year.
  • Cash from Financing Activities was $26.7 million for Q4 2025 at Travere Therapeutics, up from -$65.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $217.6 million in Q1 2023 and bottomed at -$65.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $34.1 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities surged 9137.65% in 2024, then plummeted 142141.3% in 2025.
  • Year by year, Cash from Financing Activities stood at $39.3 million in 2021, then tumbled by 98.6% to $551000.0 in 2022, then surged by 173.32% to $1.5 million in 2023, then soared by 9137.65% to $139.1 million in 2024, then plummeted by 80.82% to $26.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TVTX at $26.7 million in Q4 2025, -$65.3 million in Q3 2025, and $1.5 million in Q2 2025.